Polymyalgia Rheumatica News and Research

RSS
Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

Tocilizumab drug offers potential treatment for patients with polymyalgia rheumatics

Tocilizumab drug offers potential treatment for patients with polymyalgia rheumatics

ACR releases two new publications to improve treatment of polymyalgia rheumatica, gout

ACR releases two new publications to improve treatment of polymyalgia rheumatica, gout

Cranial ultrasound has greater sensitivity than temporal artery biopsy in diagnosis of GCA

Cranial ultrasound has greater sensitivity than temporal artery biopsy in diagnosis of GCA

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Young, middle-aged fibromyalgia patients report poorer quality of life than older patients

Young, middle-aged fibromyalgia patients report poorer quality of life than older patients

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Cardiovascular risk present across chronic rheumatic diseases

Cardiovascular risk present across chronic rheumatic diseases

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

New ACR classification criteria for polymyalgia rheumatica

New ACR classification criteria for polymyalgia rheumatica

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

BMY receives FDA approval for YERVOY to treat metastatic melanoma

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Zalicus third quarter total revenue decreases to $1.2 million

Zalicus third quarter total revenue decreases to $1.2 million

Phase 3 U.S. registration study of LODOTRA shows improvement in patients with RA

Phase 3 U.S. registration study of LODOTRA shows improvement in patients with RA

Ultrasound saves money, improves rheumatologic care

Ultrasound saves money, improves rheumatologic care